Health
Health Policy Analysis
A new analysis suggests excluding rare disease therapies from Medicare drug-pricing pilots would negate significant savings. Additionally, a Senate inquiry is probing potential policy softening related to kratom and tobacco by the Trump administration.
Coverage timeline — 2 articles
STAT News
Excluding rare disease therapies from a Medicare pilot program to lower drug prices would wipe out much of the savings from retail drugs, according to new research.
2026-08-05 08:30 UTC
STAT News
The Senate investigation includes RFK Jr. as well as the heads of Reynolds American and kratom company Botanic Tonics, asking for written responses and documentation by Aug. 31.
2026-08-05 08:30 UTC